

ORAL PRESENTATION

Open Access

Roles of beta-arrestin1/2 in prostaglandin-mediated signaling and tumor development

Robert Langenbach*, Huei-Chen Lao, Kyung-Soo Chun

From 16th International Charles Heidelberger Symposium on Cancer Research
Coimbra, Portugal. 26–28 September 2010

Prostaglandin (PG) E₂ manifest its biological activity by signalling via four G protein coupled receptors (GPCRs) identified as EP1, EP2, EP3 and EP4. GPCRs represent the most numerous class of receptors in the mammalian genome. Ligand binding to the GPCR results in the activation of the G α s subunit and disassociation of the G α s and G β γ subunits. Early on the binding of β -arrestin1 or 2 to the GPCR was thought to terminate GPCR signalling by preventing further G protein interaction and to cause receptor internalization/desensitization. However, recent studies have indicated that the GPCR/ β -arrestin1 or 2 interactions can actually provide a mechanism for GPCR-mediated signalling.

In the research to be presented, the signalling pathways activated by butaprost, an EP2 agonist, and EP2's contributions to keratinocyte replication and skin tumor development are described. Butaprost stimulation of EP2 led to the activation of PKA and down stream effectors. In addition, butaprost stimulation of EP2 led to EP2- β -arrestin1 complex formation with subsequent Src activation and transactivation of EGFR and down stream effectors. The necessity for β -arrestin1 in the activation of Src/EGFR was indicated by the significantly decreased activation of Src/EGFR and down stream effectors in β -arrestin1^{-/-} mouse skin. In addition, selective inhibition of PKA, EGFR or the use of β -arrestin1^{-/-} mice significantly reduced mouse skin tumor formation. Thus, the data indicate that the PGE₂ receptor, EP2, plays an important role in skin tumor formation; and that both G protein dependent and β -arrestin1 dependent signalling pathways are involved.

Published: 24 September 2010

doi:

Cite this article as: Langenbach et al.: Roles of beta-arrestin1/2 in prostaglandin-mediated signaling and tumor development. *BMC Proceedings* 2010 **4**(Suppl 2):O8.

* Correspondence: langenb1@niehs.nih.gov
Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
Full list of author information is available at the end of the article

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

BioMed Central